**Core tip:** In this study, we established accurate nomograms for predicting the pathological response (PR) to preoperative neoadjuvant therapy (NT) regimens based on pretreatment parameters for locally advanced rectal cancer (LARC) patients. Logistic regression and nomograms were developed to predict the probability of complete pathological response and good downstaging, respectively, for all patients and for subgroups based on NT regimens. In conclusion, nomograms have been established for predicting the PR to different NT regimens for LARC patients; and these nomograms can be used to facilitate developing individualized treatments.

INTRODUCTION
============

In recent decades, neoadjuvant therapy (NT) has been the standardized treatment for locally advanced rectal cancer (LARC)\[[@B1]\]. NT was reported to decrease the risk of local recurrence and have reduced toxicity\[[@B2],[@B3]\]. Pathological complete response (pCR) is characterized as complete elimination of malignant cells in a resected specimen\[[@B4],[@B5]\]. Approximately 8%-35% of patients with LARC who received NT was reported to have achieved pCR\[[@B6]-[@B9]\]. Researchers have also found that good pathological response are associated with a longer disease-free survival (DFS) and lower local and distant recurrence rates\[[@B10]-[@B15]\].

Individualized treatment for LARC patients can be achieved by developing an accurate model to predict the probability of pCR or good downstaging. Some authors suggest that if pCR can be accurately predicted, these patients can be strictly followed without requiring surgery\[[@B16]-[@B18]\]. Radical surgery can drastically reduce the quality of life by impairing normal intestinal and genitourinary functions\[[@B19]\]. However, other authors argue that follow-up alone is unsafe and that the pathology cannot be accurately assessed without surgery after NT\[[@B20]\]. In addition, no tumor response or progression after NT implies that the tumor is destructive, resistant to both chemotherapy and radiotherapy, and prone to having a high metastatic potential. Thus, identifying potential responders and non-responders may aid in predicting treatment outcomes and choices.

Previous studies have reported that low carcinoembryonic antigen (CEA) levels\[[@B21],[@B22]\], high pretreatment hemoglobin (HB) levels, early clinical T stage (cT)\[[@B23]\], early clinical N stage (cN), small tumor size, and long radiation surgery interval\[[@B6],[@B23]-[@B25]\] are related to pCR probability. However, few models or nomograms have been established and even fewer are used clinically to predict a good pathological response after NT for LARC. Additionally, few models are available to predict neoadjuvant treatments. Therefore, developing accurate models to predict pathological responses has great clinical significance and remains a great challenge.

In this study, by analyzing pretreatment parameters in LARC patients before NT at our institution, we established accurate models and nomograms to predict the probability of pCR and good downstaging, respectively, with currently available pretreatment parameters that can be easily used in clinical decision-making.

MATERIALS AND METHODS
=====================

Patients
--------

Rectal cancer patients were identified from the database of The Sixth Affiliated Hospital, Sun Yat-sen University from January 2012 to December 2016. Four hundred and three patients who met the following criteria were included: histopathologically confirmed rectal adenocarcinoma, \>18 years old, tumor located no more than 12 cm above the anal verge, clinical stage of cT3/4 or lymph node (+), and non-metastatic. All patients were assessed *via* abdominal-pelvic computed tomography (CT) and pelvic magnetic resonance imaging (MRI), and 44 (11%) patients received transrectal ultrasound testing. All received NT followed by total mesorectal excision (TME) radical surgery.

We collected all available clinical information before treatment: gender, age, body mass index (BMI), cT, cN, mesorectal fascia (MRF) status, tumor differentiation, tumor length (TL), distance of tumor from the anal verge (DTAV), tumor circumferential extent (TCE), serum tumor marker CEA, HB, neutrophil-lymphocyte ratio (NLR), platelets (PLT), apolipoprotein A-1 (ApoA1), apolipoprotein B (ApoB), and NT regimen type. All tumor-related parameters such as cT, cN, MRF status, DTAV, and TCE were assessed by MRI. Tumor length was also assessed by using MRI to measure the maximum diameter of tumor. CT, transrectal ultrasound, and endoscopy provided additional verification. Tumor differentiation was identified by enteroscopic pathology.

This retrospective study was approved by the Institutional Review Board of The Sixth Affiliated Hospital, Sun Yat-sen University.

Therapy
-------

During the period we identified patients for the current study, a clinical trial (FOWARC) was conducted at our institution comparing the effectiveness and safety of administering only chemotherapy with mFOLFOX6 or mFOLFOX6 plus radiotherapy to LARC patients with the effectiveness and safety in patients undergoing a standard NT regimen with fluorouracil plus radiotherapy. Consequently, 273 (67.7%) patients in our study were included in the FOWARC trial. The NT regimens included in our study were capecitabine /fluorouracil plus radiotherapy (standard group, capecitabine/deGramont-RT), mFOLFOX6 without radiotherapy (mFOLFOX6), and mFOLFOX6 plus radiotherapy (mFOLFOX6-RT). Details of all these treatments have been reported in previous studies\[[@B26],[@B27]\]. The radiation dose for the radiotherapy was 46.0-50.4 Gy, delivered as 1.8-2.0 Gy/d, and the dose was the same in the capecitabine/deGramont-RT and mFOLFOX6-RT groups. Patients in the capecitabine/deGramont-RT and mFOLFOX6-RT groups underwent standard TME radical surgery after NT. The interval between radiation and surgery was 6-12 wk in mFOLFOX6-RT and de Gramont--RT groups. The interval between chemotherapy and TME radical surgery was about 2-4 wk in the mFOLFOX6 group.

Pathological assessment
-----------------------

All resected specimens were examined to determine the post-TN staging according to the American Joint Committee on Cancer-International Union Against Cancer (seventh edition), which is currently considered the most accurate and standard staging system in this period\[[@B28]\]. pCR was defined as no malignant cells found in the resected specimens, including the primary tumor and lymph nodes, and ypT0-2N0M0 (ypTNM 0-I) was classified as good downstaging.

Statistical analysis
--------------------

Chi-square analysis was selected for the univariate logistic regression analysis of the countable data. Normal distribution tests were performed for the metrological data, nonparametric test was used for the indicators that were not normally distributed, and the expression form of the median (upper quartile to lower quartile) is used.

Parameters such as age (≤ 60 years *vs* \> 60 years), BMI (\< 25 kg/cm^2^ *vs* ≥ 25 kg/cm^2^), CEA (\> 5 ng/mL *vs* ≤ 5 ng/mL), HB (≤ 125 g/L *vs* \> 125 g/L), NLR (\> 3 *vs* ≤ 3), DTAV (\< 5 cm *vs* ≥ 5 cm) and TL (\> 3 cm *vs* ≤ 3 cm) were dichotomized according to previous studies\[[@B24],[@B29],[@B30]\]. PLT, ApoA1, ApoB, and the interval were used as continuous variables, however, all these variables were not normally distributed, so a nonparametric test was used.

Univariate logistic regression analysis was used to analyze variables related to the probability of pCR or good downstaging. Variables that achieved significance at *P* ≤ 0.05 in the univariate logistic regression analysis were further analyzed into the forward stepwise multivariable logistic regression. Multivariate logistic regression analysis was used to construct nomograms. Because the NT regimen was a statistically significant factor for predicting pCR probability, all patients were divided into three subgroups (the capecitabine/deGramont-RT, mFOLFOX6-RT, or mFOLFOX6 groups) based on the NT regimens. We then attempted to develop three nomograms based on the different NT regimens to predict pCR probability. The C-index was acquired for the nomogram, and internal validation using the bootstrap method was performed to determine the adjusted C-index. Calibration curves of the nomograms were generated to show the relationship between the predicted and observed outcomes. All statistical analyses were performed using SPSS 24.0 and R 3.5.1.

RESULTS
=======

Of the 403 patients in our study, 281 (69%) were men. As assessed pathologically, 72 (17.86%) individuals achieved pCR; 177 (43.9%) patients achieved ypTNM 0-I and were classified as having good downstaging.

The interval between radiation and surgery was 52 (47-59) d in the mFOLFOX6-RT group and 54 (49-58.25) d in the deGramont--RT group, and there was no significance difference between the two groups. The interval between chemotherapy and surgery was 22 (18-25.75) d in the mFOLFOX6 group, which was much shorter than those in the other two groups.

All patients received TME surgery (28 underwent APR and 375 underwent sphincter-saving surgery).

pCR patients and non-pCR patients did not differ significantly in terms of gender, BMI, CEA, NLR, HB, PLT, ApoA1, ApoB, cT, cN, or TCE in the univariate analysis (*P* \> 0.05); however, significant differences were found for age, tumor differentiation, TL, DTAV, MRF status, interval, and NT regimen (Table [1](#T1){ref-type="table"}). Statistically significant factors in the univariate logistic regression analysis (*P* ≤ 0.05) to predict pCR were entered into a multivariate analysis, in which NT regimen types (^a^*P* \< 0.05), tumor differentiation (^b^*P* \< 0.05), TL (^c^*P* \< 0.05), and MRF status (^d^*P* \< 0.05) were significantly associated with pCR probability (Table [2](#T2){ref-type="table"}). For the NT regimens, the odds ratio (OR) was 5.339 \[95% confidence interval (CI): 2.394-11.903\] for the mFOLFOX6-RT regimen compared with the capecitabine/deGramont-RT regimen. The mFOLFOX6 regimen and capecitabine/deGramont-RT regimen did not differ significantly. For tumor differentiation, the OR was 2.966 (95%CI: 1.449-6.069) for well tumor differentiation compared with moderate-poor differentiation. For TL (\> 3 cm) compared with TL (≤ 3 cm), the OR was 2.608 (95%CI: 1.347-5.052), and for MRF(-) compared with MRF(+), the OR was 2.729 (95%CI: 1.199-6.211).

###### 

Predictive factors for complete pathological response in univariate logistic regression analysis for all patients

  **Variable**           **Non-pCR (*n* = 331) *n* P~50~ (P~25~-P~75~)**   **pCR (*n* = 72) *n* P~50~ (P~25~-P~75~)**   **pCR rate**        ***P*-value**   
  ---------------------- ------------------------------------------------- -------------------------------------------- ------------------- --------------- -------
  Gender                 Male                                              232                                          49                  17.44%          0.653
  Female                 96                                                23                                           19.33%                              
  Age (yr)               ≤ 60                                              210                                          54                  20.45%          0.07
  \> 60                  119                                               18                                           13.14%                              
  BMI (kg/cm^2^)         \< 25                                             231                                          53                  18.66%          0.581
  ≥ 25                   78                                                15                                           16.13%                              
  Hemoglobin (g/L)       ≤ 125                                             109                                          16                  12.80%          0.126
  \> 125                 172                                               41                                           19.25%                              
  NLR                    \> 3                                              37                                           11                  22.92%          0.227
  ≤ 3                    244                                               46                                           15.86%                              
  Platelet (× 10^9^/L)                                                     237.5 (200.25-286.75)                        246 (200.5-268.5)                   0.981
  ApoA1 (g/L)                                                              1.29 (1.13-1.44)                             1.3 (1.15-1.52)                     0.454
  ApoB (g/L)                                                               0.98 (0.79-1.14)                             0.97 (0.82-1.19)                    0.382
  The interval (d)                                                         39 (22.25-54)                                50 (42-56.5)                        0
  CEA (ng/mL)            \> 5                                              163                                          28                  14.66%          0.217
  ≤ 5                    118                                               29                                           19.73%                              
  Differentiation        Moderate-poor                                     274                                          44                  13.84%          0.001
  Well                   44                                                20                                           31.25%                              
  DTAV (cm)              \< 5                                              140                                          41                  22.65%          0.024
  ≥ 5                    191                                               31                                           13.96%                              
  TL (cm)                \> 3                                              237                                          41                  14.75%          0.001
  ≤ 3                    73                                                30                                           29.13%                              
  TCE                    \< 50%                                            37                                           7                   15.91%          0.772
  ≥ 50%                  256                                               55                                           17.68%                              
  cT                     2                                                 16                                           5                   23.81%          0.405
  3                      234                                               56                                           19.31%                              
  4                      54                                                8                                            12.90%                              
  cN                     \+                                                235                                          57                  19.52%          0.465
  \-                     78                                                15                                           16.13%                              
  MRF                    \-                                                231                                          61                  20.89%          0.013
  \+                     97                                                11                                           10.19%                              
  NT regimen             Capecitabine/de Gramont-RT                        102                                          13                  11.30%          0
  mFOLFOX6               148                                               14                                           8.64%                               
  mFOLFOX6-RT            81                                                45                                           35.71%                              

Platelet, apolipoprotein A-1, apolipoprotein B, and the interval were calculated as metrological data, and others are counting data. pCR: Complete pathological response; NLR: Neutrophil-lymphocyte ratio; DTAV: Distance of tumor from the anal verge; TL: Tumor length; TCE: Tumor circumferential extent; NT: Neoadjuvant therapy; PLT: Platelet; ApoA1: Apolipoprotein A-1; ApoB: Apolipoprotein B; MRF: Mesorectal fascia; CEA: Carcinoembryonic antigen.

###### 

Predictive factors for complete pathological response in multivariate logistic regression analysis for all patients

  **Variable**                 ***P*-value**   **OR**   **95%CI**     
  ---------------------------- --------------- -------- ------------- --------------
  Age (yr)                     ≤ 60            0.703    0.873         0.434-1.756
  \> 60                                        1                      
  Differentiation              Well            0.003    2.966         1.449-6.069
  Moderate-poor                                1                      
  TL (cm)                      ≤ 3             0.004    2.608         1.347-5.052
  \> 3                                         1                      
  DTAV                         ≥ 5             0.07     0.56          0.299-1.049
  \< 5                                         1                      
  MRF                          \-              0.017    2.729         1.199-6.211
  \+                                           1                      
  NT regimen                   mFOLFOX6-RT     0        5.339         2.394-11.903
  mFOLFOX6                     0.402           1.821    0.449-7.387   
  Capecitabine/de Gramont-RT                   1                      
  The interval                                 0.093    1.029         0.995-1.064

pCR: Complete pathological response; TL: Tumor length; DTAV: Distance of tumor from the anal verge; NT: Neoadjuvant therapy; MRF: Mesorectal fascia.

Patients with good downstaging and bad downstaging did not significantly differ in terms of age, gender, BMI, NLR, HB, PLT, ApoA1, ApoB, cN, TCE, the interval, or NT regimen in the univariate analysis (*P* \> 0.05); however, significant differences were found for CEA, tumor differentiation, DTAV, TL, cT, and MRF status in the univariate logistic regression analysis for good downstaging (Table [3](#T3){ref-type="table"}). In the multivariate analysis, tumor differentiation (^e^*P* \< 0.05), MRF statuses (^f^*P* \< 0.05), and cT (^g^*P* \< 0.05) were significantly associated with the probability of good downstaging (Table [4](#T4){ref-type="table"}). The OR was 4.814 (95%CI: 2.343-9.892) for well differentiation compared with moderate-poor differentiation, 4.226 (95%CI: 1.894-9.426) for MRF(-) compared with MRF(+), and 0.248 (95%CI: 0.063-0.974) for cT3 compared with cT2.

###### 

Predictive factors for good downstaging in univariate logistic regression analysis for all patients

  **Variable**          **Bad downstaging (*n* = 226) *n* P~50~ (P~25~-P~75~)**   **Good downstaging (*n* = 177) *n* P~50~ (P~25~-P~75~)**   **Good downstaging rate**   ***P*-value**   
  --------------------- --------------------------------------------------------- ---------------------------------------------------------- --------------------------- --------------- -------
  Gender                Male                                                      164                                                        117                         41.64%          0.106
  Female                59                                                        60                                                         50.42%                                      
  Age (yr)              ≤ 60                                                      144                                                        120                         45.45%          0.462
  \> 60                 80                                                        57                                                         41.61%                                      
  BMI (kg/cm^2^)        \< 25                                                     159                                                        125                         44.01%          0.475
  ≥ 25                  56                                                        37                                                         39.78%                                      
  Hemoglobin (g/L)      ≤ 125                                                     69                                                         56                          44.80%          0.426
  \> 125                127                                                       86                                                         40.38%                                      
  NLR                   \> 3                                                      27                                                         21                          43.75%          0.792
  ≤ 3                   169                                                       121                                                        41.72%                                      
  Platelet (×10^9^/L)                                                             241 (207-294)                                              236 (193-272.25)                            0.125
  ApoA1 (g/L)                                                                     1.27 (1.13-1.44)                                           1.31 (1.15-1.48)                            0.228
  ApoB (g/L)                                                                      0.98 (0.79-1.13)                                           0.97 (0.79-1.18)                            0.88
  The interval                                                                    39 (23-54)                                                 48 (25.75-55)                               0.062
  CEA (ng/mL)           \> 5                                                      125                                                        66                          34.55%          0.002
  ≤ 5                   71                                                        76                                                         51.70%                                      
  Differentiation       Moderate-poor                                             194                                                        124                         38.99%          0
  Well                  20                                                        44                                                         68.75%                                      
  DTAV (cm)             \< 5                                                      85                                                         96                          53.04%          0.001
  ≥ 5                   141                                                       81                                                         36.49%                                      
  TL (cm)               \> 3                                                      167                                                        111                         39.93%          0.002
  ≤ 3                   44                                                        59                                                         57.28%                                      
  TCE                   \< 50%                                                    23                                                         21                          47.73%          0.508
  ≥ 50%                 179                                                       132                                                        42.44%                                      
  cT                    2                                                         4                                                          17                          80.95%          0
  3                     160                                                       130                                                        44.83%                                      
  4                     46                                                        16                                                         25.81%                                      
  cN                    \+                                                        166                                                        126                         43.15%          0.074
  \-                    43                                                        50                                                         53.76%                                      
  MRF                   \-                                                        142                                                        150                         51.37%          0
  \+                    81                                                        27                                                         25.00%                                      
  NT regimen            Capecitabine/de Gramont-RT                                64                                                         51                          44.35%          0.061
  mFOLFOX6-RT           61                                                        65                                                         51.59%                                      
  mFOLFOX6              101                                                       61                                                         37.65%                                      

Platelet, apolipoprotein A-1, apolipoprotein B, and the interval were calculated as metrological data, and others are counting data. NLR: Neutrophil-lymphocyte ratio; DTAV: Distance of tumor from the anal verge; TL: Tumor length; TCE: Tumor circumferential extent; NT: Neoadjuvant therapy; PLT: Platelet; ApoA1: Apolipoprotein A-1; ApoB: Apolipoprotein B; MRF: Mesorectal fascia; CEA: Carcinoembryonic antigen.

###### 

Predictive factors for good downstaging in multivariate logistic regression analysis for all patients

  **Variable**      ***P*-value**   **OR**   **95%CI**     
  ----------------- --------------- -------- ------------- -------------
  CEA (ng/mL)       ≤ 5             0.095    1.565         0.925-2.647
  \> 5                              1                      
  Differentiation   Well            0        4.814         2.343-9.892
  Moderate-poor                     1                      
  DTAV (cm)         ≥ 5             0.052    0.588         0.345-1.004
  \< 5                              1                      
  TL (cm)           ≤ 3             0.9      1.04          0.566-1.909
  \> 3                              1                      
  cT                3               0.046    0.248         0.063-0.974
  4                 0.127           0.282    0.056-1.434   
  2                                 1                      
  MRF               \-              0        4.226         1.894-9.426
  \+                                1                      

DTAV: Distance of tumor from the anal verge; TL: Tumor length; MRF: Mesorectal fascia; CEA: Carcinoembryonic antigen.

Because the type of NT regimen was a statistically significant factor for predicting pCR probability, patients were divided into three subgroups (the capecitabine/deGramont-RT, mFOLFOX6, and mFOLFOX6-RT groups) based on the NT regimen. Table [5](#T5){ref-type="table"} shows the distribution of pretreatment clinical parameters in the NT regimen groups. No differences were found in any factors between the three groups except age **(**^h^*P* \< 0.05**)** and DTAV **(**^i^*P* \< 0.05**)**. In the univariate analysis of the capecitabine/deGramont-RT group, NLR was the only significant factor for predicting pCR probability (Table [6](#T6){ref-type="table"}). NLR (\> 3) (^j^*P* \< 0.05) was the only significant factor, with an OR of 4.278 (95%CI: 1.051-17.413) compared with NLR ≤ 3 in the further multivariate analysis (Table [7](#T7){ref-type="table"}). We could not develop a nomogram to predict pCR probability in this case.

###### 

Distribution of pretreatment clinical parameters in different neoadjuvant therapy regimen groups

  **Variable**       **Capecitabine/deGramont-RT *n* (%) P~50~ (P~25~-P~75~)**   **mFOLFOX6 *n* (%) P~50~ (P~25~-P~75~)**   **mFOLFOX6-RT *n* (%) P~50~ (P~25~-P~75~)**   ***P*-value**      
  ------------------ ----------------------------------------------------------- ------------------------------------------ --------------------------------------------- ------------------ -------
  Gender             Male                                                        76 (66.67)                                 107 (66.88)                                   98 (77.78)         0.083
  Female             38 (33.33)                                                  53 (33.13)                                 28 (22.22)                                                       
  Age (yr)           ≤ 60                                                        66 (57.39)                                 102 (63.75)                                   96 (76.19)         0.007
  \> 60              49 (42.61)                                                  58 (36.25)                                 30 (23.81)                                                       
  BMI (kg/cm^2^)     \< 25                                                       83 (76.85)                                 118 (76.62)                                   83 (72.17)         0.641
  ≥ 25               25 (23.15)                                                  36 (23.38)                                 32 (27.83)                                                       
  Hemoglobin (g/L)   ≤ 125                                                       34 (34.34)                                 55 (39.29)                                    36 (36.36)         0.729
  \> 125             65 (65.66)                                                  85 (60.71)                                 63 (63.64)                                                       
  NLR                \> 3                                                        16 (16.16)                                 17 (12.14)                                    15 (15.15)         0.646
  ≤ 3                83 (83.84)                                                  123 (87.86)                                84 (84.85)                                                       
  CEA (ng/mL)        \> 5                                                        56 (56.57)                                 79 (56.43)                                    56 (56.57)         1
  ≤ 5                43 (43.43)                                                  61 (43.57)                                 43 (43.43)                                                       
  Differentiation    Moderate-poor                                               90 (81.08)                                 135 (87.1)                                    93 (80.17)         0.246
  Well               21 (18.92)                                                  20 (12.9)                                  23 (19.83)                                                       
  DTAV (cm)          \< 5                                                        61 (53.04)                                 62 (38.27)                                    58 (46.03)         0.049
  ≥ 5                54 (46.96)                                                  100 (61.73)                                68 (53.97)                                                       
  TL (cm)            \> 3                                                        82 (74.55)                                 105 (70)                                      91 (75.21)         0.572
  ≤ 3                28 (25.45)                                                  45 (30)                                    30 (24.79)                                                       
  TCE                \< 50%                                                      10 (10)                                    22 (15.28)                                    12 (10.81)         0.389
  ≥ 50%              90 (90)                                                     122 (84.72)                                99 (89.19)                                                       
  cN                 \+                                                          84 (75)                                    110 (73.33)                                   98 (79.67)         0.462
  \-                 28 (25)                                                     40 (26.67)                                 25 (20.33)                                                       
  MRF                \-                                                          85 (74.56)                                 119 (74.38)                                   88 (69.84)         0.627
  \+                 29 (25.44)                                                  41 (25.63)                                 38 (30.16)                                                       
  pCR                Non-pCR                                                     102 (88.7)                                 148 (91.36)                                   81 (64.29)         0
  pCR                13 (11.3)                                                   14 (8.64)                                  45 (35.71)                                                       
  Downstaging        Bad                                                         64 (55.65)                                 101 (62.35)                                   61 (48.41)         0.061
  Good               51 (44.35)                                                  61 (37.65)                                 65 (51.59)                                                       
  cT                 2                                                           9 (8.26)                                   10 (6.85)                                     2 (1.69)           0.19
  3                  85 (77.98)                                                  112 (76.71)                                93 (78.81)                                                       
  4                  15 (13.76)                                                  24 (16.44)                                 23 (19.49)                                                       
  PLT (×10^9^/L)                                                                 230 (188.75-267.25)                        236.5 (200.25-290.75)                         244 (212-281)      0.168
  ApoA1 (g/L)                                                                    1.31 (1.14-1.47)                           1.29 (1.12-1.44)                              1.28 (1.15-1.5)    0.73
  ApoB (g/L)                                                                     0.97 (0.8-1.09)                            0.98 (0.78-1.14)                              0.98 (0.81-1.21)   0.425
  The interval                                                                   54 (49-58.25)                              22 (18-25.75)                                 52 (47-59)         0

Platelet, apolipoprotein A-1, apolipoprotein B, and the interval were calculated as metrological data, and others are counting data. pCR: Complete pathological response; NLR: Neutrophil-lymphocyte ratio; DTAV: Distance of tumor from the anal verge; TL: Tumor length; TCE: Tumor circumferential extent; NT: Neoadjuvant therapy; PLT: Platelet; ApoA1: Apolipoprotein A-1; ApoB: Apolipoprotein B; MRF: Mesorectal fascia; CEA: Carcinoembryonic antigen.

###### 

Predictive factors for complete pathological response in univariate logistic regression analysis for the capecitabine/deGramont-RT regimen

  **Variable**       **Non-pCR (*n* = 102) *n* P~50~ (P~25~-P~75~)**   **pCR (*n* = 13) *n* P~50~ (P~25~-P~75~)**   **pCR rate**       ***P-*value**   
  ------------------ ------------------------------------------------- -------------------------------------------- ------------------ --------------- -------
  Gender             Male                                              70                                           6                  7.89%           0.096
  Female             31                                                7                                            18.42%                             
  Age (yr)           ≤ 60                                              56                                           10                 15.15%          0.131
  \> 60              46                                                3                                            6.12%                              
  BMI (kg/cm^2^)     \< 25                                             75                                           8                  9.64%           0.375
  ≥ 25               21                                                4                                            16.00%                             
  Hemoglobin (g/L)   ≤ 125                                             33                                           1                  2.94%           0.087
  \> 125             56                                                9                                            13.85%                             
  NLR                \> 3                                              12                                           4                  25.00%          0.031
  ≤ 3                77                                                6                                            7.23%                              
  PLT (×10^9^/L)                                                       228 (188.25-266.75)                          252 (188.75-319)                   0.338
  ApoA1 (g/L)                                                          1.3 (1.14-1.48)                              1.34 (1.11-1.46)                   0.912
  ApoB (g/L)                                                           0.97 (0.8-1.09)                              0.92 (0.78-1.02)                   0.667
  The interval                                                         53.97 ± 8.94                                 52.38 ± 10.79                      0.588
  CEA (ng/mL)        \> 5                                              51                                           5                  8.93%           0.659
  ≤ 5                38                                                5                                            11.63%                             
  Differentiation    Moderate-poor                                     82                                           8                  8.89%           0.177
  Well               17                                                4                                            19.05%                             
  DTAV (cm)          \< 5                                              52                                           9                  14.75%          0.214
  ≥ 5                50                                                4                                            7.41%                              
  TL (cm)            \> 3                                              74                                           8                  9.76%           0.252
  ≤ 3                23                                                5                                            17.86%                             
  TCE                ≤ 50%                                             10                                           0                  0.00%           0.241
  \> 50%             79                                                11                                           12.22%                             
  cT                 2                                                 7                                            2                  22.22%          0.521
  3                  75                                                10                                           11.76%                             
  4                  14                                                1                                            6.67%                              
  cN                 \+                                                73                                           11                 13.10%          0.394
  \-                 26                                                2                                            7.14%                              
  MRF                \-                                                74                                           11                 12.94%          0.377
  \+                 27                                                2                                            6.90%                              

Platelet, apolipoprotein A-1, apolipoprotein B, and the interval were calculated as metrological data, and others are counting data. pCR: Complete pathological response; NLR: Neutrophil-lymphocyte ratio; DTAV: Distance of tumor from the anal verge; TL: Tumor length; TCE: Tumor circumferential extent; PLT: Platelet; ApoA1: Apolipoprotein A-1; ApoB: Apolipoprotein B; MRF: Mesorectal fascia; CEA: Carcinoembryonic antigen.

###### 

Predictive factors for complete pathological response in multivariate logistic regression analysis for the capecitabine/deGramont-RT regimen

  **Variable**   ***P* value**   **OR**   **95%CI**   
  -------------- --------------- -------- ----------- --------------
  NLR            \> 3            0.042    4.278       1.051-17.413
  ≤ 3                            1                    

NLR: Neutrophil-lymphocyte ratio.

Table [8](#T8){ref-type="table"} shows that TL and MRF status were significant factors predicting pCR probability in the univariate analysis of the mFOLFOX6-RT regimen. TL (^k^*P \<* 0.05) and MRF(+) (^l^*P* \< 0.05) were significant factors, with an OR of 2.452 (95%CI: 1.015-5.926) for TL(≤ 3 cm) compared with TL(\> 3 cm) and an OR of 3.829 (95%CI: 1.42-10.325) for MRF(-) compared with MRF(+) in the further multivariate analysis (Table [9](#T9){ref-type="table"}).

###### 

Predictive factors for complete pathological response in univariate logistic regression analysis for the mFOLFOX6-RT regimen

  **Variable**       **Non-pCR (*n* = 81) *n* P~50~ (P~25~-P~75~)**   **pCR (*n* = 45) *n* P~50~ (P~25~-P~75~)**   **pCR rate**       ***P*-value**   
  ------------------ ------------------------------------------------ -------------------------------------------- ------------------ --------------- -------
  Gender             Male                                             63                                           35                 35.71%          1
  Female             18                                               10                                           35.71%                             
  Age (yr)           ≤ 60                                             62                                           34                 35.42%          0.901
  \> 60              19                                               11                                           36.67%                             
  BMI (kg/cm^2^)     \< 25                                            49                                           34                 40.96%          0.202
  ≥ 25               23                                               9                                            28.13%                             
  Hemoglobin (g/L)   ≤ 125                                            23                                           13                 36.11%          0.905
  \> 125             41                                               22                                           34.92%                             
  NLR                \> 3                                             9                                            6                  40.00%          0.683
  ≤ 3                55                                               29                                           34.52%                             
  PLT (×10^9^/L)                                                      246.5 (214.25-289.75)                        239 (197-269)                      0.22
  ApoA1 (g/L)                                                         1.26 (1.15-1.44)                             1.3 (1.15-1.55)                    0.453
  ApoB (g/L)                                                          1 (0.81-1.24)                                0.97 (0.81-1.17)                   0.725
  The interval                                                        51.5 (43-58.75)                              54 (50-62)                         0.116
  CEA (ng/mL)        \> 5                                             40                                           16                 28.57%          0.107
  ≤ 5                24                                               19                                           44.19%                             
  Differentiation    Moderate-poor                                    63                                           30                 32.26%          0.311
  Well               13                                               10                                           43.48%                             
  DTAV (cm)          \< 5                                             33                                           25                 43.10%          0.11
  ≥ 5                48                                               20                                           29.41%                             
  TL (cm)            \> 3                                             64                                           27                 29.67%          0.008
  ≤ 3                13                                               17                                           56.67%                             
  TCE                \< 50%                                           8                                            4                  33.33%          0.944
  ≥ 50%              65                                               34                                           34.34%                             
  cT                 2                                                0                                            2                  100.00%         0.061
  3                  58                                               35                                           37.63%                             
  4                  18                                               5                                            21.74%                             
  cN                 \+                                               62                                           36                 36.73%          0.946
  \-                 16                                               9                                            36.00%                             
  MRF                \-                                               49                                           39                 44.32%          0.002
  \+                 32                                               6                                            15.79%                             

Platelet, apolipoprotein A-1, apolipoprotein B, and the interval were calculated as metrological data, and others are counting data. pCR: Complete pathological response; NLR: Neutrophil-lymphocyte ratio; DTAV: Distance of tumor from the anal verge; TL: Tumor length; TCE: Tumor circumferential extent; PLT: Platelet; ApoA1: Apolipoprotein A-1; ApoB: Apolipoprotein B; MRF: Mesorectal fascia; CEA: Carcinoembryonic antigen.

###### 

Predictive factors for complete pathological response in multivariate logistic regression analysis for the mFOLFOX6-RT regimen

  **Variable**   ***P* value**   **OR**   **95%CI**   
  -------------- --------------- -------- ----------- -------------
  TL (cm)        ≤ 3             0.046    2.452       1.015-5.926
  \> 3                           1                    
  MRF            \-              0.008    3.829       1.42-10.325
  \+                             1                    

TL: Tumor length; MRF: Mesorectal fascia.

In the univariate analysis of the mFOLFOX6 regimen, tumor differentiation and TL were significant factors for predicting pCR probability (Table [10](#T10){ref-type="table"}). Further multivariate analysis showed that differentiation (^m^*P* \< 0.05) and TL (^n^*P* \< 0.05) were significant factors, with an OR of 8.881 (95%CI: 2.263-34.85) for well tumor differentiation compared with moderate-poor differentiation and an OR of 4.805 (95%CI: 1.25-18.466) for TL (≤ 3 cm) compared with TL (\> 3 cm) (Table [11](#T11){ref-type="table"}).

###### 

Predictive factors for complete pathological response in univariate logistic regression analysis for the mFOLFOX6 regimen

  **Variable**       **Non-pCR (*n* = 148) *n* P~50~ (P~25~-P~75~)**   **pCR (*n* = 14) *n* P~50~ (P~25~-P~75~)**   **pCR rate**         ***P*-value**   
  ------------------ ------------------------------------------------- -------------------------------------------- -------------------- --------------- -------
  Gender             Male                                              99                                           8                    7.48%           0.418
  Female             47                                                6                                            11.32%                               
  Age (yr)           ≤ 60                                              92                                           10                   9.80%           0.532
  \> 60              54                                                4                                            6.90%                                
  BMI (kg/cm^2^)     \< 25                                             107                                          11                   9.32%           0.477
  ≥ 25               34                                                2                                            5.56%                                
  Hemoglobin (g/L)   ≤ 125                                             53                                           2                    3.64%           0.093
  \> 125             75                                                10                                           11.76%                               
  NLR                \> 3                                              16                                           1                    5.88%           0.673
  ≤ 3                112                                               11                                           8.94%                                
  PLT (×10^9^/L)                                                       127.5 (117.5-139)                            137.5 (127-142.25)                   0.82
  ApoA1 (g/L)                                                          1.28 (1.11-1.42)                             1.3 (1.15-1.46)                      0.542
  ApoB (g/L)                                                           0.96 (0.77-1.13)                             1.13 (0.86-1.3)                      0.051
  The interval                                                         21.5 (18-25)                                 25 (19.25-26.75)                     0.09
  CEA (ng/mL)        \> 5                                              72                                           7                    8.86%           0.889
  ≤ 5                56                                                5                                            8.20%                                
  Differentiation    Moderate-poor                                     129                                          6                    4.44%           0
  Well               14                                                6                                            30.00%                               
  DTAV (cm)          \< 5                                              55                                           7                    11.29%          0.345
  ≥ 5                93                                                7                                            7.00%                                
  TL (cm)            \> 3                                              99                                           6                    5.71%           0.02
  ≤ 3                37                                                8                                            17.78%                               
  TCE                \< 50%                                            19                                           3                    13.64%          0.413
  ≥ 50%              112                                               10                                           8.20%                                
  cT                 2                                                 9                                            1                    10.00%          0.974
  3                  101                                               11                                           9.82%                                
  4                  22                                                2                                            8.33%                                
  cN                 \+                                                100                                          10                   9.09%           0.866
  \-                 36                                                4                                            10.00%                               
  MRF                \-                                                108                                          11                   9.24%           0.707
  \+                 38                                                3                                            7.32%                                

Platelet, apolipoprotein A-1, apolipoprotein B, and the interval were calculated as metrological data, and others are counting data. pCR: Complete pathological response; NLR: Neutrophil-lymphocyte ratio; DTAV: Distance of tumor from the anal verge; TL: Tumor length; TCE: Tumor circumferential extent; PLT: Platelet; ApoA1: Apolipoprotein A-1; ApoB: Apolipoprotein B; MRF: Mesorectal fascia; CEA: Carcinoembryonic antigen.

###### 

Predictive factors for complete pathological response in multivariate logistic regression analysis for the mFOLFOX6 regimen

  **Variable**      ***P-*value**   **OR**   **95%CI**   
  ----------------- --------------- -------- ----------- -------------
  Differentiation   Well            0.002    8.881       2.263-34.85
  Moderate-poor                     1                    
  TL                ≤ 3             0.022    4.805       1.25-18.466
  \> 3                              1                    

TL: Tumor length.

Predictive nomograms established for pCR and good downstaging
-------------------------------------------------------------

Nomograms were developed based on the significant factors in the multivariate logistic regression analysis. The nomogram for predicting pCR probability showed that NT regimen and tumor differentiation influenced the probability of pCR, followed by TL and MRF status (Figure [1](#F1){ref-type="fig"}). When developing the nomogram to predict the probability of good downstaging, tumor differentiation and MRF status were the most important, followed by cT (Figure [2](#F2){ref-type="fig"}). We attempted to develop three nomograms to predict pCR probability based on NT regimens, because only one significant factor was found for the capecitabine/deGramont-RT regimen, we could not develop a nomogram. MRF status and TL were the significant factors for the mFOLFOX6-RT group (Figure [3](#F3){ref-type="fig"}). For the mFOLFOX6 group, tumor differentiation and TL were the significant factors in the nomogram for predicting pCR probability (Figure [4](#F4){ref-type="fig"}). Using the nomograms, we could easily calculate the probability of pCR and ypTNM (0-I), and we calculated pCR probabilities based on the NT regimens.

![Nomogram for predicting the probability of pathological complete response for all patients. MRF: Mesorectal fascia.](WJG-25-118-g001){#F1}

![Nomogram for predicting the probability of good downstaging (ypTNM stage 0-I) for all patients. MRF: Mesorectal fascia.](WJG-25-118-g002){#F2}

![Nomogram for predicting the probability of pathological complete response for the mFOLFOX6-RT regimen. MRF: Mesorectal fascia.](WJG-25-118-g003){#F3}

![Nomogram for predicting the probability of pathological complete response for the mFOLFOX6 regimen.](WJG-25-118-g004){#F4}

We used 1000 bootstrap resamples to compute an adjusted C-index, which was 79.34% for predicting pCR (95%CI: 73.48%-85.21%) for all patients, with a C-index of 69.85% (95%CI: 60.94%-78.76%) for the mFOLFOX6-RT group and 83.39% (95%CI: 67.26%-93.52%) for the mFOLFOX6 group. For predicting good downstaging, the adjusted C-index was 68.08% (95%CI: 63.08%-73.07%) for all patients. Calibration curves between predicted and actual observations by internal validation demonstrated that these nomograms showed good statistical performance for predicting the probability of pCR and good downstaging. Figures [5](#F5){ref-type="fig"} [6](#F6){ref-type="fig"} [7](#F7){ref-type="fig"} and [8](#F8){ref-type="fig"} show the calibration curve between the predicted and actual observations by internal validation and demonstrates that these nomograms showed good statistical performance for predicting the probability of pCR and good downstaging.

![Calibration curve of the predicted and observed probabilities of pathological complete response for all patients.](WJG-25-118-g005){#F5}

![Calibration curve of the predicted and observed probabilities of good downstaging for all patients.](WJG-25-118-g006){#F6}

![Calibration curve of the predicted and observed probabilities of pathological complete response for the mFOLFOX6-RT regimen.](WJG-25-118-g007){#F7}

![Calibration curve of the predicted and observed probabilities of pathological complete response for the mFOLFOX6 regimen.](WJG-25-118-g008){#F8}

DISCUSSION
==========

At present, preoperative NT is the standard treatment for patients with LARC. Patients who respond well to preoperative treatment have shown to have an excellent long-term prognosis. Knowledge of these factors ultimately leads to individualized treatment strategies; for example, patients who do not respond to the usual management can choose an aggressive preoperative regimen before NT. Conversely, to accurately determine an excellent pathological response after NT, surgeons may choose to perform local excision or a "watch and wait" strategy. In some cases, radical surgical resection may not benefit for some patients who achieve a good response because radical surgical resection may be associated with high rates of temporary or permanent stomas, defecatory disorders, urinary and sexual dysfunction, and unnecessary mortality\[[@B31],[@B32]\]. pCR after NT is reported to have an excellent long-term prognosis irrespective of the treatment strategy, so noninvasive treatment strategies, such as a "watch and wait" strategy, have become more popular for patients who achieve a good response\[[@B33],[@B34]\]. Thus, understanding the factors that predict the pathological response to NT is becoming crucial.

Our study identified clinical variables related to the pCR and good downstaging of LARC patients after NT. In the nomogram, we demonstrated that type of NT regimen, tumor differentiation, MRF status, and TL predicted pCR, whereas tumor differentiation, MRF status, and cT predicted good downstaging.

In our model, the mFOLFOX6-RT group had a higher probability of pCR compared with the capecitabine/de Gramont-RT group. We acknowledge that a potential selection bias may contribute to this high pCR rate. The data missing were more frequently in patients not reaching pCR than those with pCR, possibly resulting from more attentions pCR-patients got in clinical practice, follow-up, or research work. The pCR rate was 35.7% for mFOLFOX6-RT, which is higher than that of FOWARC\[[@B26],[@B27]\]. It is expected since this is a single-center statistic result, while the FORWARC trial is a muli-center study. Although the benefits of oxaliplatin have not been demonstrated and it is not part of standard NT regimens, oxaliplatin is a standard component of chemotherapy for treating colon cancer\[[@B35]\]. Importantly, it has been reported in more and more studies\[[@B36],[@B37]\] that the regimen combining mFOLFOX 6 with RT is getting a higher pCR rate of 38% in a clinical trial published in Lancet Oncology\[[@B38]\]. However, the role of oxaliplatin adding to fluorouracil-based neoadjuvant chemoradiotherapy (CRT) is unclear for LARC patients, and more studies are needed in the future.

pCR probabilities did not significantly differ between the capecitabine/deGramont-RT and themFOLFOX6 groups. Additionally, NT regimen was not a significant factor for predicting the probability of good downstaging. To avoid radiotherapeutic harm to LARC patients, the use of neoadjuvant chemotherapy alone has been proposed. Our model showed that patients treated with the mFOLFOX6 regimen alone had an acceptable probability of pCR and good downstaging. Thus, some chemosensitive patients can avoid radiation therapy.

Tumor differentiation was associated with both pCR and good downstaging. Well differentiation was associated with a higher pCR probability, which is consistent with previous studies\[[@B23],[@B39]\], and was related to good downstaging compared with moderate-poor differentiation. Patients with a well differentiated tumor have a higher pCR probability indicating that a mild NT regimen, local resection, or "watch and wait" strategy can be considered after NT. Patients with moderate-poor differentiation may have a poor likelihood of pCR and good downstaging indicating that a "watch and wait" strategy requires careful selection.

Factors associated with pCR and good downstaging both included MRF status. MRF(+) implies that the tumor is aggressive, and even after NT, patients with MRF(+) may have a poor likelihood of pCR and good downstaging, indicating that an enhanced NT regimen and radical surgery are needed and a "watch and wait" strategy requires careful selection. While patients with MRF(-) may have a higher pCR probability indicating that a mild NT regimen, local resection, or "watch and wait" strategy can be considered after NT.

TL was also a significant factor in the multivariate logistic regression analysis for predicting pCR probability in all patients. Van Stiphout et al\[[@B40]\] reported that TL was related to the probability of pCR after NT, although this study was based on data from positron emission tomography (PET)-CT results. TL (\> 3 cm) implies an aggressive tumor, and even after NT, patients with TL (\> 3 cm) may have a lower pCR probability indicating that an enhanced NT regimen and radical surgery are needed. While for patients with TL (≤ 3 cm) may have a higher pCR probability indicating that a mild NT regimen, local resection, or "watch and wait" strategy can be considered after NT.

For predicting the probability of good downstaging, cT was also a significant factor in the multivariate logistic regression analysis. In a study performed by Joye et al\[[@B41]\], a low cT stage was linked with ypT0-1N0, and it, together with other factors, could be used as a selection tool for organ-preserving strategies. Our study also showed that low cT stage was more likely to achieve good downstaging with NT, and indicated that less invasive surgery can be selected.

For the capecitabine/de Gramont-RT regimen, the only significant factor was the NLR. Kim et al\[[@B42]\] showed that an elevated NLR before CRT can be used to predict poor tumor response and adverse prognostic factors. As lymphocytes decrease and neutrophils increase, NLR affects the adverse tumor reaction and adverse prognosis. Our study showed that the NLR before NT was related to better pathological responses to the capecitabine/deGramont-RT regimen; thus, further studies are needed to validate the relationship between NLR and pathological response to NT.

For the mFOLFOX6-RT regimen, the significant factors for predicting pCR probability were MRF status and TL. MRF(+) and long TL indicated that the tumor was aggressive and patients have heavy tumor load, and were related to poor neoadjuvant pathological responses. Patients with moderate-poor differentiation and TL (\> 3 cm) have a lower pCR probability indicating that the efficacy of CRT is poor for these patients, and radical surgery can be directly selected without NT to avoid complications caused by CRT.

For the mFOLFOX6 regimen, the nomogram for predicting pCR probability showed that differentiation and TL were significant factors. Poor differentiation and long TL indicated an aggressive tumor, and they were related to a poor neoadjuvant pathological response. Patients with moderate-poor differentiation and TL (\> 3 cm) will have a lower probability of pCR indicating that radical surgery after NT is needed, or mFOLFOX6-RT regimen is chosen to increase pCR probability. However, good differentiation and short TL were related to a good neoadjuvant pathological response and high probability of pCR indicating that local resection or a "watch and wait" strategy can be chosen.

To the best of our knowledge, our study is the first to use different NT regimen types to predict a pathological response. We established an accurate model with easily obtained variables to predict the probability of pCR and good downstaging. Our analysis was also strengthened through cross-validation. These models can be used to assist with individualized therapy as follows. For LARC patients expected to have a poor pathological response, NT and NT-related harm can be avoided. For patients expected to have good pathological responses to chemotherapy alone, radiotherapy can be avoided. For patients who are not expected to have good pathological response from a standard NT regimen, an enhanced mFOFOLX6-RT regimen can be considered. For patients who are not expected to have good pathological response from an enhanced regimen, radical surgery can be directly chosen without NT to avoid complications caused by CRT. For patients with a high probability of pCR after NT, local resection or a "watch and wait" strategy can be used to avoid complications.

Our analysis had several limitations. First, this was a retrospective study, in which some factors associated with pCR were unavailable, such as smoking status, molecular subtype and so on. Second, mFOLFOX6 and mFOLFOX6-RT are not the standard regimens for LARC, and both regimens remain in the clinical trial phase. Finally, our nomograms are based on the experience of our single institution. These results must be validated in a group of independent external institutions.

The nomograms established in our study can be used to evaluate the probability of a pathological responses before NT and after NT. However, additional studies are required to answer clinical questions, regarding which patients can be treated only with neoadjuvant chemotherapy, which patients need oxaliplatin added to the neoadjuvant CRT, which patients need radical surgery, which patients can undergo local excision, and which patients can be managed with a "watch and wait" strategy after achieving a good response.

We established accurate nomograms to predicting the pathological responses to different preoperative NT regimens based on pretreatment parameters for LARC patients. These nomograms can be used to distinguish patient types and facilitate developing individualized treatments.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

In recent decades, neoadjuvant therapy (NT) has been the standardized treatment for locally advanced rectal cancer (LARC). Approximately 8-35% of patients with LARC who received NT were reported to have achieved a complete pathological response (pCR). If the pathological response can be accurately predicted, these patients may not need surgery. In addition, no response after NT implies that the tumor is destructive, resistant to both chemotherapy and radiotherapy, and prone to having a high metastatic potential.

Few models or nomograms have been established and even fewer are used clinically to predict a good pathological response after NT for LARC. Therefore, developing accurate models to predict pathological response (PR) has great clinical significance and can help achieve individualized treatment in LARC patients.

Research motivation
-------------------

Our goal was to establish nomograms that can be used to assist with individualized therapy as follows: for which patients NT and NT-related harm can be avoided; which patients will have good pathological responses to chemotherapy alone and radiotherapy can be avoided; which patients will have a good pathological response from a standard NT regimen, which patients need an enhanced mFOFOLX6-RT regimen; and which patients can use local resection or a "watch and wait" strategy to avoid complications. Solving these problems may aid in clinical treatment choices.

Research objectives
-------------------

Our main objective was to establish nomograms for predicting a pathological response to different NT regimens based on pretreatment parameters for patients with LARC. We established accurate nomograms for predicting the pathological response to preoperative NT regimens based on pretreatment parameters for LARC patients. These nomograms can be used to distinguish patient types and facilitate developing individualized treatments.

Research methods
----------------

Rectal cancer patients were identified from the database of The Sixth Affiliated Hospital, Sun Yat-sen University from January 2012 to December 2016. Four hundred and three patients who met the criteria were included. We collected all available clinical information before treatment.

The NT regimens included in our study were capecitabine/fluorouracil plus radiotherapy (standard group, capecitabine/deGramont-RT), mFOLFOX6 without radiotherapy (mFOLFOX6), and mFOLFOX6 plus radiotherapy (mFOLFOX6-RT). The radiation dose for the radiotherapy was 46.0-50.4 Gy, delivered as 1.8-2.0 Gy/d.

pCR was defined as no malignant cells found in the resected specimens, including the primary tumor and lymph nodes, and ypT0-2N0M0 (ypTNM 0-I) was classified as good downstaging.

Univariate logistic regression analysis was used to analyze variables related to the probability of pCR or good downstaging. Variables that achieved significance at *P* ≤ 0.05 in the univariate logistic regression analysis were further analyzed into the forward stepwise multivariable logistic regression. Multivariate logistic regression analysis was used to construct the nomograms. Because the NT regimen was a statistically significant factor for predicting pCR probability, we then attempted to develop three nomograms based on the different NT regimens to predict pCR probability. The C-index was acquired for the nomogram, and internally validated using the bootstrap method to determine the adjusted C-index. Calibration curves of the nomograms were generated to show the relationship between the predicted and observed outcomes.

All statistical analyses were performed using SPSS 24.0 and R 3.5.1.

Research results
----------------

Of the 403 patients in our study, 281 (69%) were men. As assessed pathologically, 72 (17.86%) individuals achieved a pCR; 177 (43.9%) patients achieved ypTNM 0-I and were classified as having good downstaging.

Significant differences were found for age, tumor differentiation, TL, DTAV, mesorectal fascia (MRF) status, interval, and NT regimen in the univariate analysis. In the multivariate analysis, NT regimen types, tumor differentiation, TL, and MRF status were significantly associated with pCR probability.

Significant differences were found for carcinoembryonic antigen (CEA), tumor differentiation, distance of tumor from the anal verge (DTAV), tumor length (TL), cT, and MRF status in the univariate logistic regression analysis for good downstaging. In the multivariate analysis, tumor differentiation, MRF statuses, and cT were significantly associated with the probability of good downstaging.

Table 5 shows the distribution of pretreatment clinical parameters in the NT regimen groups. No differences were found in any factors between the three groups except age and DTAV.

In the univariate analysis of the capecitabine/deGramont-RT group, NLR was the only significant factor for predicting pCR probability. NLR (\> 3) was the only significant factor compared with NLR ≤ 3 in the further multivariate analysis. We could not develop a nomogram to predict pCR probability in this case.

In the univariate analysis of the mFOLFOX6-RT regimen, TL and MRF status were significant factors predicting pCR probability. TL and MRF(+) were significant factors in multivariate analysis.

In the univariate analysis of the mFOLFOX6 regimen, tumor differentiation and TL were significant factors for predicting pCR probability. Further multivariate analysis showed that differentiation and TL were significant factors.

Nomograms were developed based on the significant factors in the multivariate logistic regression analysis. We used 1000 bootstrap resamples to compute an adjusted C-index. Calibration curves between predicted and actual observations by internal validation demonstrated that these nomograms showed good statistical performance for predicting the probability of pCR and good downstaging.

Research conclusions
--------------------

We established accurate nomograms to predicting the pathological responses to different preoperative NT regimens based on pretreatment parameters for LARC patients. These nomograms can be used to distinguish patient types and facilitate developing individualized treatments.

To the best of our knowledge, our study is the first to use different NT regimen types to predict a pathological response. We established an accurate model with easily obtained variables to predict the probability of pCR and good downstaging. Our analysis was also strengthened through cross-validation. These models can be used to assist with individualized therapy as follows. For LARC patients expected to have a poor pathological response, NT and NT-related harm can be avoided. For patients expected to have good pathological responses to chemotherapy alone, radiotherapy can be avoided. For patients who are not expected to have good pathological response from a standard NT regimen, an enhanced mFOFOLX6-RT regimen can be considered. For patients with a high probability of pCR after NT, local resection or a "watch and wait" strategy can be used to avoid complications.

Our analysis had several limitations. First, this was a retrospective study, in which some factors associated with pCR were unavailable, such as smoking status, molecular subtypes and so on. Second, mFOLFOX6 and mFOLFOX6-RT are not the standard regimens for LARC, and both regimens remain in the clinical trial phase. Finally, our nomograms are based on the experience of our single institution. These results must be validated in a group of independent external institutions.

The nomograms established in our study can be used to evaluate the probability of a pathological responses before NT and after NT. However, additional studies are required to answer clinical questions regarding which patients can be treated only with neoadjuvant chemotherapy, which patients need oxaliplatin added to the neoadjuvant chemoradiotherapy, which patients need radical surgery, which patients can undergo local excision, and which patients can be managed with a "watch and wait" strategy after achieving a good response.

Research perspectives
---------------------

In the future, we plan to include a larger number of patients to enhance the accuracy of the prediction. On the other hand, we plan to add a second external cohort for validation to strengthen the reliability of the nomogram.

Manuscript source: Invited manuscript

Specialty type: Gastroenterology and hepatology

Country of origin: China

Peer-review report classification

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

Institutional review board statement: This study was reviewed and approved by the Ethics Committee of The Sixth Affiliated Hospital, Sun Yat-sen University.

Informed consent statement: Patients were not required to give informed consent for the study because the analysis used anonymous clinical data obtained via written consent after each patient agreed to treatment.

Conflict-of-interest statement: We have no financial relationships to disclose.

Data sharing statement: No additional data are available.

Peer-review started: October 17, 2018

First decision: November 22, 2018

Article in press: December 19, 2018

P- Reviewer: Gerard JP, Young CJ S- Editor: Ma RY L- Editor: Wang TQ E- Editor: Huang Y

[^1]: Author contributions: Luo YX, Yu HC, and Ren DL designed the research; Peng SY, Lin WD, Li J, Ghoorun RA, and Wang XL performed the research; Yu HC and Li J contributed analytic tools; Ren DL and Li J analyzed the data; Ren DL and Li J wrote the paper.

    Supported by National Basic Research Program of China (973 Program), No. 2015CB554001; National Natural Science Foundation of China, No. 81472257 and No. 81502022; Natural Science Fund for Distinguished Young Scholars of Guangdong Province, No. 2016A030306002; Tip-top Scientific and Technical Innovative Youth Talents of Guangdong Special Support Program, No. 2015TQ01R454; Natural Science Foundation of Guangdong Province, No. 2016A030310222 and No. 2018A0303130303; Science and Technology Program of Guangzhou, No. 201506010099 and No. 2014Y2-00160; Science and Technology Program of Guangdong Province, No. 2014A020215011; Fundamental Research Funds for the Central Universities (Sun Yat-sen University), No. 2015ykzd10 and No. 16ykpy35; Program of Introducing Talents of Discipline to Universities; and National Key Clinical Discipline.

    Corresponding author: Yan-Xin Luo, MD, PhD, Associate Professor, Chief Doctor, Surgical Oncologist, Department of Colorectal Surgery, Guangdong Institute of Gastroenterology, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, 26 Yuancun Erheng Road, Tianhe District, Guangzhou 510655, Guangdong Province, China. <luoyx25@mail.sysu.edu.cn>

    Telephone: +86-13826190263 Fax: +86-20-38254221
